1-7 of 7
Jamie H. Hirata
Close
Sort by
Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Franck Morschhauser, Wilfred Leung, Vibha Raghavan, Georg Lenz, Fabrice Jardin, Alex F. Herrera, Laurie H. Sehn, Jeff P. Sharman, Christopher R. Flowers, Jonathan W. Friedberg, Marek Trněný, Hervé Tilly, Charles Herbaux, Samuel Tracy, Christopher R. Bolen, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Gilles Salles
Journal: Blood
Blood (2023) 142 (Supplement 1): 3000.
https://doi.org/10.1182/blood-2023-178623
Published: 2023
Journal Articles

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Fabrice Jardin, Vibha Raghavan, Samuel Tracy, Sandhya Balasubramanian, Laurie H. Sehn, Christopher R. Flowers, Franck Morschhauser, Alex F. Herrera, Marek Trněný, Jeff P. Sharman, Gilles Salles, Hervé Tilly, Jonathan W. Friedberg, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Georg Lenz
Journal: Blood
Blood (2023) 142 (Supplement 1): 169.
https://doi.org/10.1182/blood-2023-178564
Published: 2023
Journal Articles

A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States

Loretta Nastoupil, MD, Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Brian K Link, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Christopher R Flowers, MD
Journal: Blood
Blood (2011) 118 (21): 97.
https://doi.org/10.1182/blood.V118.21.97.97
Published: 2011
Journal Articles

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Nutan J. DeJoubner, MD, Ajay K. Nooka, MD, MPH, FACP, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Brian K Link, MD, Christopher R Flowers, MD
Journal: Blood
Blood (2011) 118 (21): 775.
https://doi.org/10.1182/blood.V118.21.775.775
Published: 2011
Journal Articles

Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004–2007,

Loretta Nastoupil, MD, Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Xiaolei Zhou, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Brian K Link, MD, Jamie H. Hirata, PharmD, Christopher R Flowers, MD
Journal: Blood
Blood (2011) 118 (21): 3708.
https://doi.org/10.1182/blood.V118.21.3708.3708
Published: 2011
Journal Articles

Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)

Christopher R Flowers, MD, MS, Michael Taylor, PharmD, PhD, Michelle Byrtek, PhD, Jamie H. Hirata, PharmD, James Cerhan, MD, PhD, John Hainsworth, MD, Brian Link, Thomas P. Miller, MD, Hildy Dillon, MPH, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2010) 116 (21): 1768.
https://doi.org/10.1182/blood.V116.21.1768.1768
Published: 2010
Journal Articles

Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently? Report From the National LymphoCare Study (NLCS)

Chadi Nabhan, MD, FACP, Michelle Byrtek, Ph.D., Michael Taylor, PharmD, PhD, Jill Tydell, MD, Jamie H. Hirata, PharmD, Christopher R Flowers, MD, MS
Journal: Blood
Blood (2010) 116 (21): 4152.
https://doi.org/10.1182/blood.V116.21.4152.4152
Published: 2010